FederalForecastedFood and Drug Administration

Novel approaches to support therapeutic development in ultra-rare cancers

Award ceiling
Not stated
Closes
Not stated
Last verified
2026-10-22

Per-recipient award not stated for city or township governments, county governments, for profit organizations other than small businesses, independent school districts, native american tribal governments (federally recognized), native american tribal organizations (other than federally recognized tribal governments), nonprofits having a 501(c)(3) status with the irs, other than institutions of higher education, nonprofits that do not have a 501(c)(3) status with the irs, other than institutions of higher education, private institutions of higher education, public and state controlled institutions of higher education, public housing authorities/indian housing authorities, small businesses, special district governments, state governments.

Official pageSign in to trackVerified2026-10-22
City or township governmentsCounty governmentsFor profit organizations other than small businessesIndependent school districtsNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPrivate institutions of higher educationPublic and State controlled institutions of higher educationPublic housing authorities/Indian housing authoritiesSmall businessesSpecial district governmentsState governmentsAgricultureConsumer ProtectionFood & Nutrition

In one sentence

Novel approaches to support therapeutic development in ultra-rare cancers does not state a per-recipient award amount, open to city or township governments, county governments, for profit organizations other than small businesses, independent school districts, native american tribal governments…

Record fields
Program pool (total)
Not confirmed
Total across all awards in this programme. Not an amount any single applicant can receive.
Award ceiling (per project)
Not confirmed
Award floor
Not confirmed
Typical award
Not confirmed
Deadline
Not stated
Deadline type
Not stated
Opens
Not stated
Status
Forecasted
Eligible entities
City or township governments · County governments · For profit organizations other than small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · Special district governments · State governments
Geography
Not stated
Matching funds
No
Disbursement
Not confirmed
Application effort
Not confirmed
Use of funds
Development of infrastructure for coordination networks and data repositories for ultra-rare cancers · Investigations to explore early clinical endpoints and novel efficacy endpoints for ultra-rare cancer treatments · Development of collaborative multi-stakeholder efforts for real-world data registries for pediatric diffuse midline glioma · Innovative approaches to identify new opportunities for clinical development of previously approved drugs in ultra-rare cancers · Research to develop novel approaches to preserve availability of discontinued drugs for ultra-rare cancers · Development of telemedicine and pragmatic trial design methods for patient enrollment in ultra-rare cancer studies · Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors · Research to characterize plasma-membrane protein expression of ultra-rare cancers and healthy tissue of origin
Currency
USD

How much money is available?

Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.

Program pool (total)Across all awards this cycle
Not stated
Award ceiling (per project)The most one applicant can receive
Not stated

Who can apply?

level
federal
Derived from the source that published this record
entity
City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Public and State controlled institutions of higher education
+4more, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments
Source field: entity types
industry
use
Development of collaborative multi-stakeholder efforts for real-world data registries for pediatric diffuse midline glioma, Development of infrastructure for coordination networks and data repositories for ultra-rare cancers, Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors, Development of telemedicine and pragmatic trial design methods for patient enrollment in ultra-rare cancer studies, Innovative approaches to identify new opportunities for clinical development of previously approved drugs in ultra-rare cancers, Investigations to explore early clinical endpoints and novel efficacy endpoints for ultra-rare cancer treatments, Research to characterize plasma-membrane protein expression of ultra-rare cancers and healthy tissue of origin, Research to develop novel approaches to preserve availability of discontinued drugs for ultra-rare cancers
Source field: use of funds
size limit

Not confirmed

Source field: applicant size limit
clause text

Not confirmed

We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.

When does it close?

Not statedDeadline type Not stated

What can the money be used for?

8 categorysThe source’s own spending categories, and what is not parsed.
Development of infrastructure for coordination networks and data repositories for ultra-rare cancersInvestigations to explore early clinical endpoints and novel efficacy endpoints for ultra-rare cancer treatmentsDevelopment of collaborative multi-stakeholder efforts for real-world data registries for pediatric diffuse midline gliomaInnovative approaches to identify new opportunities for clinical development of previously approved drugs in ultra-rare cancersResearch to develop novel approaches to preserve availability of discontinued drugs for ultra-rare cancersDevelopment of telemedicine and pragmatic trial design methods for patient enrollment in ultra-rare cancer studiesDevelopment of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factorsResearch to characterize plasma-membrane protein expression of ultra-rare cancers and healthy tissue of origin

These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.

How hard is the application?

1 fieldEffort, match requirement and reimbursement, as the source stated them.
Application effort
Not confirmed
Disbursement
Not confirmed
Matching funds
No

What comparable notices state

62 recordsStated ceilings on open records in the same industry.

Among open records stored under Agriculture, 62 of 76 state an award ceiling. Those that do run:

  • 25th percentile$300,000
  • Median$1,000,000
  • 75th percentile$2,000,000

A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.

Who has won this programme before?

1262 awardsAwards under the same assistance listing, not under this notice.

1262 federal awards on file under assistance listing 93.103, the programme this notice is published under. These are not awards made under this notice — a listing covers every year the programme runs, and awards under an open notice do not exist yet.

Every award under this programme

Common questions

3 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
Who is eligible to apply?
City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments.
What can the funding be used for?
Development of infrastructure for coordination networks and data repositories for ultra-rare cancers, Investigations to explore early clinical endpoints and novel efficacy endpoints for ultra-rare cancer treatments, Development of collaborative multi-stakeholder efforts for real-world data registries for pediatric diffuse midline glioma, Innovative approaches to identify new opportunities for clinical development of previously approved drugs in ultra-rare cancers, Research to develop novel approaches to preserve availability of discontinued drugs for ultra-rare cancers, Development of telemedicine and pragmatic trial design methods for patient enrollment in ultra-rare cancer studies, Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors, Research to characterize plasma-membrane protein expression of ultra-rare cancers and healthy tissue of origin, as classified by the source.
Is matching funding required?
No. The source states that no matching funds are required.

AI summary of the source text

Optional. Every core field on this record is already above, free and complete.

AI summary of the source text

Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.

Included with Studio

Sign in

What else is open

Also open under assistance listing 93.103

A listing names the programme; a notice names one round of it. These are other rounds open now, not other years of this one.

Provenance
Source pagegrants.gov
Retrieved2026-10-22
MethodAutomated check
First seen2026-09-04
Assistance listing93.103

The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.